| Pre- and post-infection vaccine | Post-infection vaccine | |||
---|---|---|---|---|---|
Resistance status | Outcome | 2030 | 2050 | 2030 | 2050 |
RR/MDR-TB | % Incidence rate reduction in year | 44% (42–46) | 73% (66–76) | 14% (13–16) | 29% (27–31) |
% Mortality rate reduction in year | 22% (18–24) | 67% (59–72) | 8% (6–10) | 28% (25–30) | |
Cumulative cases averted, millions | 0.2 (0.1–0.2) | 2.1 (1.1–2.7) | 0.05 (0.04–0.06) | 0.7 (0.5–0.9) | |
Cumulative deaths averted, millions | 0.003 (0.001–0.005) | 0.1 (0.0–0.2) | 0.001 (0.001–0.002) | 0.04 (0.02–0.06) | |
All TB | % Incidence rate reduction in year | 42% (40–44) | 56% (53–59) | 28% (26–29) | 37% (35–38) |
% Mortality rate reduction in year | 29% (26–32) | 53% (48–58) | 21% (18–24) | 35% (33–36) | |
Cumulative cases averted, millions | 1.4 (1.2–1.5) | 10.5 (8.9–12.0) | 0.9 (0.8–1.0) | 6.9 (5.9–7.8) | |
Cumulative deaths averted, millions | 0.02 (0.01–0.04) | 0.4 (0.2–0.5) | 0.02 (0.01–0.03) | 0.3 (0.1–0.4) |